Evaluation of efficiency of screening extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in hospitals where the bacteria are increasingly prevalent.
The disk screening methods for extended-spectrum beta-lactamase-producing strains were evaluated. The confirmatory work is reduced significantly in settings such as those in this study, by changing the cefpodoxime breakpoint to < or =20 mm and by not testing cefoxitin-resistant isolates. Cefotaxime and ceftazidime disk screening is reliable, and the laboratory-prepared cefotaxime- and ceftazidime-clavulanic acid disks are stable at -20 degrees C for 12 weeks.
Lee
K
K
Department of Clinical Pathology, Research Institute of Bacterial Resistance, and BK21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul, Korea.
Lim
J K
JK
Yong
D
D
Yum
J
J
Chong
Y
Y
Okamoto
R
R
Inoue
M
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002439:Cefotaxime / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D019818:Clavulanic Acid / Q000494:pharmacology; D004355:Drug Stability; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology; D006761:Hospitals; D006801:Humans; D007710:Klebsiella Infections / Q000453:epidemiology / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D015995:Prevalence; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000187:drug effects
D000900:Anti-Bacterial Agents; D019818:Clavulanic Acid; D002442:Ceftazidime; D001618:beta-Lactamases; D002439:Cefotaxime